TLR7 and diffuse large B-cell lymphoma: IMO-8400, an antisense oligonucleotide TLR inhibitor, has been shown to specifically target TLR7, TLR8, and TLR in preclinical studies and is effective in reducing the size of Waldenstrom macroglobulinemia (WM) and diffuse large B-cell lymphoma (DLBCL) xenografts, driven by gain-of-function MYD88 mutations [138].